{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=SOLID+TUMORS&page=39", "query": { "condition": "SOLID TUMORS", "page": 39 }, "page_size": 10 }, "pagination": { "page": 39, "page_size": 10, "total_count": 5453, "total_pages": 546, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=SOLID+TUMORS&page=40&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=SOLID+TUMORS&page=38&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-16T18:38:23.802Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04731467", "title": "A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor", "Non Small Cell Lung Cancer", "Pancreatic Cancer", "Ovarian Cancer", "Papillary Thyroid Cancer", "Melanoma", "Colorectal Adenocarcinoma" ], "interventions": [ { "name": "CM-24 and Nivolumab - Dose Escalation", "type": "DRUG" }, { "name": "CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion", "type": "DRUG" }, { "name": "CM-24, Nivolumab, and Nal-IRI/5-FU/LV - Expansion", "type": "DRUG" }, { "name": "Nivolumab, Nab paclitaxel and Gemcitabine - Expansion", "type": "DRUG" }, { "name": "Nivolumab and Nal-IRI/5-FU/LV - Expansion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Famewave Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 79, "start_date": "2021-03-19", "completion_date": "2024-09-30", "has_results": false, "last_update_posted_date": "2024-12-27", "last_synced_at": "2026-10-16T18:38:23.802Z", "location_count": 5, "location_summary": "Scottsdale, Arizona • Aurora, Colorado • New Haven, Connecticut + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04731467" }, { "nct_id": "NCT07291011", "title": "A Mindfulness-Based Stress Reduction Program for Improving Mental Health Outcomes for Underserved Cancer Patients in Minnesota", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hematopoietic and Lymphatic System Neoplasm", "Malignant Solid Neoplasm" ], "interventions": [ { "name": "Electronic Health Record Review", "type": "OTHER" }, { "name": "Mindfulness Relaxation", "type": "BEHAVIORAL" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER", "BEHAVIORAL" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 45, "start_date": "2025-11-05", "completion_date": "2029-11-15", "has_results": false, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-10-16T18:38:23.802Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT07291011" }, { "nct_id": "NCT01648764", "title": "A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has Spread", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Solid Tumor", "Solid Tumor", "Metastatic Tumor" ], "interventions": [ { "name": "LY2334737", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 73, "start_date": "2008-09", "completion_date": "2012-11", "has_results": true, "last_update_posted_date": "2019-06-17", "last_synced_at": "2026-10-16T18:38:23.802Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01648764" }, { "nct_id": "NCT05098132", "title": "Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Non Small Cell Lung Cancer", "Untreated Advanced NSCLC", "1st Line NSCLC" ], "interventions": [ { "name": "STK-012", "type": "DRUG" }, { "name": "pembrolizumab KEYTRUDA®", "type": "DRUG" }, { "name": "pemetrexed", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Synthekine", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 364, "start_date": "2022-01-25", "completion_date": "2029-01", "has_results": false, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-10-16T18:38:23.802Z", "location_count": 33, "location_summary": "Tucson, Arizona • Beverly Hills, California • Fullerton, California + 26 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05098132" }, { "nct_id": "NCT03860207", "title": "Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neuroblastoma", "Osteosarcoma", "Other Solid Tumor Cancers" ], "interventions": [ { "name": "Humanized 3F8 Bispecific Antibody", "type": "BIOLOGICAL" }, { "name": "Blood draw", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Y-mAbs Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "17 Years", "sex": "ALL", "summary": "1 Year to 17 Years" }, "enrollment_count": 12, "start_date": "2019-02-22", "completion_date": "2021-10-20", "has_results": true, "last_update_posted_date": "2023-09-13", "last_synced_at": "2026-10-16T18:38:23.802Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03860207" }, { "nct_id": "NCT04282044", "title": "Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor, Adult", "Triple Negative Breast Cancer", "Colorectal Cancer", "Hepatocellular Carcinoma", "Osteosarcoma", "Epithelial Ovarian Cancer", "Gastric Cancer", "Non-small Cell Lung Cancer", "Malignant Melanoma" ], "interventions": [ { "name": "CRX100 suspension for infusion", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "COMBINATION_PRODUCT" }, { "name": "Cyclophosphamide", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "BIOLOGICAL", "COMBINATION_PRODUCT" ], "sponsor": "BioEclipse Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2021-01-08", "completion_date": "2026-10", "has_results": false, "last_update_posted_date": "2024-02-08", "last_synced_at": "2026-10-16T18:38:23.802Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • La Jolla, California • Stanford, California", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04282044" }, { "nct_id": "NCT05219734", "title": "MRD Assay Evaluates Recurrence and Response Via a Tumor Informed Assessment", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer", "Solid Tumor", "Non Small Cell Lung Cancer", "Colorectal Cancer", "Bladder Cancer" ], "interventions": [ { "name": "Personalized Cancer Monitoring (PCM)", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Invitae Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 400, "start_date": "2021-11-29", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2024-03-12", "last_synced_at": "2026-10-16T18:38:23.802Z", "location_count": 2, "location_summary": "Columbus, Indiana • Jacksonville, North Carolina", "locations": [ { "city": "Columbus", "state": "Indiana" }, { "city": "Jacksonville", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05219734" }, { "nct_id": "NCT03935893", "title": "Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Cancer", "Colorectal Cancer", "Pancreatic Cancer", "Sarcoma", "Mesothelioma", "Neuroendocrine Tumors", "Squamous Cell Cancer", "Merkel Cell Carcinoma", "Mismatch Repair Deficiency", "Microsatellite Instability" ], "interventions": [ { "name": "Tumor Infiltrating Lymphocytes (TIL)", "type": "BIOLOGICAL" }, { "name": "Fludarabine + Cyclophosphamide combination", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Udai Kammula", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 20, "start_date": "2019-12-03", "completion_date": "2038-06-30", "has_results": false, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-10-16T18:38:23.802Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03935893" }, { "nct_id": "NCT00994500", "title": "Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Childhood Burkitt Lymphoma", "Childhood Central Nervous System Choriocarcinoma", "Childhood Central Nervous System Germ Cell Tumor", "Childhood Central Nervous System Germinoma", "Childhood Central Nervous System Mixed Germ Cell Tumor", "Childhood Central Nervous System Teratoma", "Childhood Central Nervous System Yolk Sac Tumor", "Childhood Choroid Plexus Tumor", "Childhood Craniopharyngioma", "Childhood Diffuse Large Cell Lymphoma", "Childhood Immunoblastic Large Cell Lymphoma", "Childhood Medulloepithelioma", "Childhood Meningioma", "Childhood Mixed Glioma", "Childhood Nasal Type Extranodal NK/T-cell Lymphoma", "Childhood Oligodendroglioma", "Recurrent Childhood Anaplastic Large Cell Lymphoma", "Recurrent Childhood Brain Stem Glioma", "Recurrent Childhood Central Nervous System Embryonal Tumor", "Recurrent Childhood Cerebellar Astrocytoma", "Recurrent Childhood Cerebral Astrocytoma", "Recurrent Childhood Ependymoma", "Recurrent Childhood Grade III Lymphomatoid Granulomatosis", "Recurrent Childhood Large Cell Lymphoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Malignant Germ Cell Tumor", "Recurrent Childhood Medulloblastoma", "Recurrent Childhood Pineoblastoma", "Recurrent Childhood Small Noncleaved Cell Lymphoma", "Recurrent Childhood Subependymal Giant Cell Astrocytoma", "Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor", "Recurrent Childhood Visual Pathway and Hypothalamic Glioma", "Recurrent Childhood Visual Pathway Glioma", "Recurrent/Refractory Childhood Hodgkin Lymphoma", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "vorinostat", "type": "DRUG" }, { "name": "bortezomib", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 20, "start_date": "2009-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-07-02", "last_synced_at": "2026-10-16T18:38:23.802Z", "location_count": 6, "location_summary": "Chicago, Illinois • Boston, Massachusetts • New York, New York + 3 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00994500" }, { "nct_id": "NCT02507544", "title": "A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma", "Advanced Cancer" ], "interventions": [ { "name": "TRX-818 capsules", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TaiRx, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2015-09", "completion_date": "2019-05-20", "has_results": false, "last_update_posted_date": "2020-05-21", "last_synced_at": "2026-10-16T18:38:23.802Z", "location_count": 2, "location_summary": "Grand Rapids, Michigan • San Antonio, Texas", "locations": [ { "city": "Grand Rapids", "state": "Michigan" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02507544" } ] }